Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations

Affiliations

• ¹ Section of Cardiorespiratory and Internal Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy ppa@unife.it.
• ² Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
• ³ Global Clinical Development, Chiesi USA, Inc., Cary, NC, USA.
• ⁴ Section of Cardiorespiratory and Internal Medicine, Dept of Medical Sciences, University of Ferrara, Ferrara, Italy.
• ⁵ COPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.